Form 4: Molina Healthcare CEO Zubretsky Reports Stock Transactions

Molina Healthcare's President and CEO, Joseph M. Zubretsky, reported the acquisition of 66,417 restricted shares and the disposition of 8,597 shares for tax withholding purposes.

Summary

• Joseph M. Zubretsky, President & CEO and Director of Molina Healthcare, Inc. (MOH), reported transactions occurring on March 1, 2026, under a Rule 10b5-1 plan.
• Disposed of 8,597 shares of common stock at a price of $154.05 per share to cover tax withholding obligations arising from the vesting of 20,623 shares.
• Acquired 66,417 shares of restricted stock at a volume-weighted average price (VWAP) of $145.75 per share, granted under the Issuer's 2025 Equity Incentive Plan.
• Following these transactions, Zubretsky directly owns 99,015 shares and indirectly owns 257,715 shares through the Joseph M. Zubretsky Revocable Trust.
• The newly granted 66,417 shares will vest in one-third increments on March 1, 2027, March 1, 2028, and March 1, 2029.
• Additional shares of 13,075 will vest on March 1, 2027, and 7,497 shares will vest on March 1, 2028.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a routine compensation event for a senior executive. The grant of new restricted stock aligns management's interests with long-term shareholder value, while the tax-related disposition is a standard practice.

Positives

• Grant of 66,417 restricted shares to the President & CEO, aligning management's long-term interests with shareholder value.
• The grant is part of the Issuer's 2025 Equity Incentive Plan, indicating a structured approach to executive compensation and incentives.

Negatives

• Disposition of 8,597 shares of common stock for tax withholding purposes, which reduces direct beneficial ownership.

Industry Context

StockSavvy.ai notes that insider transactions, such as the grant of restricted stock to a CEO, are common practices in the healthcare industry to align executive incentives with long-term company performance. The disposition of shares for tax purposes is a routine event associated with equity compensation vesting.

Corporate Governance

Stakeholder Impact

• Shareholders: The grant of restricted stock aligns the CEO's long-term interests with shareholder value. The tax-related disposition is a routine event with minimal direct impact on other shareholders.
• Employees: The equity incentive plan suggests a framework for employee and executive compensation, potentially impacting morale and retention.

Next Steps

• Vesting of 66,417 newly granted shares in one-third increments on March 1, 2027, March 1, 2028, and March 1, 2029.
• Vesting of 13,075 additional shares on March 1, 2027.
• Vesting of 7,497 additional shares on March 1, 2028.

Key Dates

Recommendation

This Form 4 filing details routine executive compensation activities, specifically the grant of restricted stock and a tax-related disposition. It does not provide new information regarding the company's operational performance, financial health, or strategic direction that would warrant a change in investment recommendation. The transactions are expected and align with standard corporate governance practices for incentivizing management.

Keywords

Molina Healthcare, MOH, Joseph M. Zubretsky, Insider Trading, Form 4, Restricted Stock, Equity Incentive Plan, Stock Grant, CEO Stock, Director Stock, Healthcare Stock